Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of VB15010 tablets in advanced solid tumors
CTR20243267Phase 2Active
- Sponsor
- Shenzhen Yangli Pharmaceutical Technology Co. Ltd.
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vb15010 in Nonhematologic neoplasms, breast cancer, prostate cancer (PCa), ovarian cancer, pancreatic cancer (PC), sponsored by Shenzhen Yangli Pharmaceutical Technology Co. Ltd.. Started Oct 2024; status: active.
02
Drugs
vb15010
03
Conditions
Nonhematologic neoplasmsbreast cancerprostate cancer (PCa)ovarian cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20243267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243267.